Objective Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus confers a risk of significant coagulopathy, with the resulting development of venous …

COVID‐19 (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) is associated
with coagulopathy through numerous mechanisms. The reported incidence of venous …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …

Abstract Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome coronavirus‐2, which has posed a significant threat to global …

Objectives: Recent studies have reported a high prevalence of thrombotic events in
coronavirus disease 2019. However, the significance of thromboembolic complications has …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …

Abstract Corona virus 2 (SARS-CoV2/Severe Acute Respiratory Syndrome Corona Virus 2)
infection has emerged as a global health crisis. Incidence of thromboembolic disease is …

Abstract Purpose of Review Novel coronavirus disease 2019 (COVID-19) has been
associated with an increased risk of arterial and venous thromboembolic (VTE) diseases …

Abstract Severe coronavirus (COVID-19) infection has been reportedly associated with a
high risk of thromboembolism. Developing macrovascular thrombotic complications …

Background Venous thromboembolism (VTE) is a potentially fatal complication of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and thromboprophylaxis …